Suppression of GCH1 Sensitizes Ovarian Cancer and Breast Cancer to PARP Inhibitor

Figure 2

GCH1 was increased upon niraparib treatment at transcriptional and translational levels. GCH1 transcription was analyzed by (a) qRT-PCR in MDA-MB-231, A2780 and HCC38 cell lines after treated with 10 μM niraparib for 48 h. The expression of GCH1 was measured by (b) western blot in MDA-MB-231, A2780 and HCC38 cell lines after treated with 10 μM niraparib for 72 h. (c) Representative immunofluorescence images of GCH1 expression in control group and cells treated with 10 μM niraparib for 72 h. (d) Representative images of IHC staining of GCH1 in human ovarian and breast cancer tissues derived from PDX models are shown, and GCH1 expression was quantified according to the IHC score.

(a)

(b)

(c)

(d)